MindMed

MindMed is a neuropharmaceutical company that discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness, and alleviate suffering. The company's approach is to use psychedelic substances in a controlled, therapeutic context.

History

MindMed was founded in 2019 by JR Rahn and Stephen Hurst, two entrepreneurs with a background in the technology industry. The company was established with the aim of developing psychedelic-inspired medicines. MindMed became the first psychedelic pharmaceutical company to be listed on the NASDAQ in April 2021.

Research and Development

MindMed's research and development efforts are focused on the therapeutic potential of psychedelic substances such as LSD, MDMA, DMT, and psilocybin. The company is conducting clinical trials to investigate the potential of these substances to treat a variety of mental health conditions, including anxiety, depression, and addiction.

Clinical Trials

MindMed is currently conducting multiple Phase II clinical trials to evaluate the safety and efficacy of its psychedelic-inspired medicines. These trials are being conducted in accordance with the guidelines established by the Food and Drug Administration (FDA) and other regulatory bodies.

Partnerships

MindMed has established partnerships with several academic institutions, including the University Hospital Basel's Liechti Lab in Switzerland, to conduct research on psychedelic substances. The company is also collaborating with the Digital Medicine division of the University Hospital Basel to develop a digital therapeutic platform for psychedelic therapies.

Criticism and Controversy

Despite the potential therapeutic benefits of psychedelic substances, their use in medicine has been controversial due to their association with recreational drug use and potential for abuse. However, MindMed and other companies in the psychedelic medicine space argue that these substances can be used safely and effectively in a controlled, therapeutic context.

- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC

Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.